Display options
Cite
Pawlikowski M, Fuss-Chmielewska J, Jaranowska M, et al. Expression of follicle stimulating hormone receptors (FSHR) in thyroid tumours - a marker of malignancy?. Thyroid Res. 2015;8(1):1doi: 10.1186/s13044-015-0014-6.
Pawlikowski, M., Fuss-Chmielewska, J., Jaranowska, M., Pisarek, H., Kubiak, R., & Winczyk, K. (2015). Expression of follicle stimulating hormone receptors (FSHR) in thyroid tumours - a marker of malignancy?. Thyroid research, 8(1), 1. https://doi.org/10.1186/s13044-015-0014-6
Pawlikowski, Marek, et al. "Expression of follicle stimulating hormone receptors (FSHR) in thyroid tumours - a marker of malignancy?." Thyroid research vol. 8,1 (2015): 1. doi: https://doi.org/10.1186/s13044-015-0014-6
Pawlikowski M, Fuss-Chmielewska J, Jaranowska M, Pisarek H, Kubiak R, Winczyk K. Expression of follicle stimulating hormone receptors (FSHR) in thyroid tumours - a marker of malignancy?. Thyroid Res. 2015 Feb 05;8(1):1. doi: 10.1186/s13044-015-0014-6. eCollection 2015. PMID: 25685198; PMCID: PMC4328168.
Copy Download .nbib Format: NLM
Share it on

Thyroid Res. 2015 Feb 05;8(1):1. doi: 10.1186/s13044-015-0014-6. eCollection 2015.

Expression of follicle stimulating hormone receptors (FSHR) in thyroid tumours - a marker of malignancy?.

Thyroid research

Marek Pawlikowski, Julita Fuss-Chmielewska, Maria Jaranowska, Hanna Pisarek, Robert Kubiak, Katarzyna Winczyk

Affiliations

  1. Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Lodz, Poland.
  2. Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Lodz, Poland.
  3. Department of Pathology of Tumors, Chair of Oncology, Medical University of Lodz, Lodz, Poland.

PMID: 25685198 PMCID: PMC4328168 DOI: 10.1186/s13044-015-0014-6

Abstract

BACKGROUND: In normal conditions FSHR are expressed in granulosa cells of the ovary and Sertoli cells of the testis. They can be expressed also in gonadal tumours. However, recently the expression of FSHR was found in tumoral cells and intra-tumoral blood vessels of many other tumours, including thyroid tumours. Aim of this study was to see whether the expression of FSHR can be useful in the differentiation of benign and malignant thyroid lesions.

METHODS: 44 samples of surgically excised thyroids were immunostained with anti- FSHR antibody raised against 1-190 amino acid sequence from the human FSHR.

RESULTS: Non-neoplastic thyroid follicles (i.e. the follicles situated outside the tumour) do not show the immunostaining for FSHR. The same concerns the majority of follicular adenomas. In contrast, 87.5% of follicular cancers, the same percentage of papillary cancers and all the examined undifferentiated cancers showed the FSHR immunopositivity of tumoral cells. A tendency towards the higher frequency of FSHR - positive blood vessels also concerns malignant thyroid tumours.

CONCLUSIONS: The ectopic FSHR immunostaining seems to be useful to differentiate malignant from benign lesions, especially follicular cancers from follicular adenomas. However, the further studies on larger material are needed.

References

  1. J Urol. 1999 Mar;161(3):970-6 - PubMed
  2. Mol Cell Endocrinol. 2010 Nov 25;329(1-2):56-61 - PubMed
  3. J Gynecol Oncol. 2010 Jun;21(2):119-24 - PubMed
  4. Endocr Relat Cancer. 2010 Nov 30;18(1):13-26 - PubMed
  5. J Cell Physiol. 2011 Jun;226(6):1608-19 - PubMed
  6. N Engl J Med. 2010 Oct 21;363(17):1621-30 - PubMed
  7. J Endocrinol Invest. 2013 Mar;36(3):174-9 - PubMed
  8. Folia Histochem Cytobiol. 2012 Oct 08;50(3):325-30 - PubMed
  9. Histopathology. 2013 Jul;63(1):29-35 - PubMed
  10. Endokrynol Pol. 2013;64(4):268-71 - PubMed
  11. Pathol Res Pract. 2014 Dec;210(12):830-5 - PubMed
  12. Endokrynol Pol. 2014;65(6):469-71 - PubMed
  13. Arch Med Sci. 2015 Dec 10;11(6):1314-7 - PubMed

Publication Types